| Autor: |
Wei, XiaoXia, Zhuang, Jing, Li, Na, Zheng, Bin, Sun, Hong, Cai, JiaQin, Huang, Xuhui, Zhang, Guifeng, Zhuang, Jie |
| Zdroj: |
International Journal of Hematology; Feb2022, Vol. 115 Issue 2, p278-286, 9p |
| Abstrakt: |
Objective: The cost-effectiveness of NUDT15 genetic testing-guided initial 6-mercaptopurine (6-MP) dosing in children with acute lymphoblastic leukemia (ALL) was evaluated. Methods: A decision tree model was used to evaluate the cost to China's medical system per quality-adjusted life-year (QALY) gained and cost per case of severe leukopenia avoided of NUDT15 genetic testing using public clinical data. Results: Genetic testing-guided initial 6-MP dosing reduced overall costs by $518.61, and prevented 0.221 cases of Grade III–IV leukopenia and increased QALY by 0.00136 per patient. Results were robust in one-way analyses and probabilistic sensitivity analyses. Conclusion: NUDT15 genetic testing prior to the initial administration of 6-MP in pediatric ALL patients in China is less expensive than standard dosing without genetic testing. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink